Accuracy of Preoperative Contrast-enhanced Cone Beam Breast CT in Assessment of Residual Tumor after Neoadjuvant Chemotherapy: A Comparative Study with Breast MRI-Reference-Cited by-同舟云学术

Accuracy of Preoperative Contrast-enhanced Cone Beam Breast CT in Assessment of Residual Tumor after Neoadjuvant Chemotherapy: A Comparative Study with Breast MRI

Published:2023-09 Issue:9 Volume:30 Page:1805-1815
ISSN:1076-6332
Container-title:Academic Radiology
language:en
Short-container-title:Academic Radiology

Author:

Wang Yafei,Zhao Mengran,Ma Yue,Liu Aidi,Zhu Yueqiang,Yin Lu,Liang Zhiran,Qu Zhiye,Lu Hong,Ma Ying,Ye Zhaoxiang

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging

Reference36 articles.

1. Breast cancer, version 3.2022, nccn clinical practice guidelines in oncology;Gradishar;J Natl Compr Canc Netw,2022

2. Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers;Pusztai;Lancet Oncol,2019

3. Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes;Volders;Breast Cancer Res Treat,2018

4. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials;Lancet Oncol,2018

5. Role of MRI to assess response to neoadjuvant therapy for breast cancer;Reig;J Magn Reson Imaging,2020

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dedicated Breast CT: Getting Ready for Prime Time;Journal of Breast Imaging;2024-08-31

2. Performance evaluation of ML models for preoperative prediction of HER2-low BC based on CE-CBBCT radiomic features: A prospective study;Medicine;2024-06-14

3. Emerging Clinical Applications for Cone Beam Breast CT: Changing the Breast Imaging Paradigm;Current Breast Cancer Reports;2024-03-18

4. Pre-treatment Contrast-enhanced Cone Beam Breast CT Imaging Features Combining with Clinicopathological Characteristics to Predict the Response of Neoadjuvant Chemotherapy: A Preliminary Feasibility Study;2024-03-18

5. Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer;The Oncologist;2024-03-09